Regulation of Apoptosis and Cell Cycle Progression by MCL1

THE JOURNAL OF BIOLOGICAL CHEMISTRY © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

Vol. 275, No. 50, Issue of December 15, pp. 39458 –39465, 2000 Printed in U.S.A.

Regulation of Apoptosis and Cell Cycle Progression by MCL1 DIFFERENTIAL ROLE OF PROLIFERATING CELL NUCLEAR ANTIGEN* Received for publication, July 25, 2000, and in revised form, September 6, 2000 Published, JBC Papers in Press, September 7, 2000, DOI 10.1074/jbc.M006626200

Kenichi Fujise‡§¶, Di Zhang‡, Juinn-lin Liu储, and Edward T. H. Yeh‡§ From the ‡Research Center for Cardiovascular Diseases, Institute of Molecular Medicine for Prevention of Human Diseases, §Divisions of Cardiology and Molecular Medicine, Department of Internal Medicine, University of Texas Health Science Center, Houston, and 储Department of Neuro-oncology, M. D. Anderson Cancer Center, Houston, Texas 77030

Apoptosis and cell cycle progression are closely linked processes under rigorous control. The integrated molecular mechanism to control apoptosis and cell cycle progression, namely the existence of regulatory molecule(s) that interface between apoptosis and cell cycle progression, has been implicated and extensively investigated. One such protein participating in the regulation of both apoptosis and cell cycle progression is p53, a tumor suppresser protein. Intriguingly, p53 transcriptionally activates both p21Waf1/Cip1, a cell cycle inhibitor (1), and pro-apoptosis genes, such as bax (2), noxa (3), fas (4), and p53-inducible genes (5). The p21Waf1/Cip1 is a dual cell cycle inhibitor, functioning as an inhibitor of cyclin-dependent kinases (CDKs)1 and of prolifer* This work was supported in part by National Institutes of Health Mentored Scientist Development Award KO8, 1KO8 HL04015-01. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ¶ To whom correspondence should be addressed: 6431 Fannin St., Suite 4200, Houston, TX 77030. Tel.: 713-500-6661; Fax: 713-500-6647; E-mail: [email protected]. 1 The abbreviations used are: CDKs, cyclin-dependent kinases; PCNA, proliferating cell nuclear antigen; Bcl-2, B-cell lymphoma-leukemia 2; MCL1, myeloid cell leukemia 1; PEST, proline (P)-, glutamic acid (E)-, serine (S)-, and threonine (T)-rich; PCR, polymerase chain

ating cell nuclear antigen (PCNA) (1). On the other hand, the activation of bax, noxa, fas, and p53-inducible genes causes cells to undergo apoptosis (2–5). Although the exact mechanism by which p53 preferentially activates genes related to either cell cycle progression or apoptosis induction is unclear, an emerging body of evidence suggests that the phosphorylation of p53 plays a critical role in the selective activation of certain genes by inducing the distinctive conformational change to and modifying the binding site preference of p53 (6). Another example of molecules that participate both in apoptosis and cell cycle regulation is the E2F (7) family proteins. Transcription factors of the E2F family, composed of E2F-1E2F-5, have been suggested to play a key role in the regulation of cell cycle progression (8). Importantly, E2F transcriptionally activates both genes that regulate the S-phase entry, including c-myc (9), cyclin D (10), cyclin E (11), and genes related to DNA synthesis, including dihydrofolate reductase (12), thymidine kinase (13), and DNA polymerase ␣ (10). In addition to its cell cycle regulatory function, E2F-1, one of the E2F family proteins, also functions as an apoptosis regulator. The overexpression of E2F-1 triggers apoptosis. The E2F-1⫺/⫺ mice exhibit an excess of mature T cells due to a defect in thymocyte apoptosis (7). Taken together, E2F family proteins may function as both apoptosis and cell cycle regulators. Still another example of the integrated control of apoptosis and cell cycle progression is Survivin, one of the inhibitor of apoptosis protein family members (14). Originally, Survivin was found to prevent cells from undergoing apoptosis upon cytokine deprivation (14). Subsequently, it was shown that Survivin was highly up-regulated in the G2/M-phase of the cell cycle (15). Survivin was found to be associated with microtubules and sustained cell survival during the G2/M-phase (15). Thus, Survivin functions as a cell cycle regulatory protein and as an apoptosis inhibitor. The above evidence, along with other evidence, suggests that the molecules that regulate apoptosis can participate in the cell cycle regulation and vice versa. It is possible that proteins originally thought to regulate apoptosis may also have a role in cell cycle regulation. The B-cell lymphoma-leukemia 2 (Bcl-2) protein family represents one of the major groups of apoptosis regulatory proteins, sharing the same structural characteristics (16, 17). At least 15 Bcl-2 family members have been identified in mammalian cells (18). Despite their structural similarities, Bcl-2 family members can either facilitate cell survival (pro-survival Bcl-2 subfamily) or promote cell death (pro-apoptosis Bax and reaction; SD, synthetic dropout; X-gal, 5-bromo-4-chloro-3-indeolyl ␤-Dgalactopyranoside; HA, influenza hemagglutinin; DTT, dithiothreitol; EGFP, enhanced green fluorescent protein; DAPI, 4,6-diamidino-2-phenylindole; BrdUrd, bromodeoxyuridine; RF-C, replication factor-C.

39458

This paper is available on line at http://www.jbc.org

Downloaded from http://www.jbc.org/ by guest on July 17, 2015

MCL1 (ML1 myeloid cell leukemia 1), a Bcl-2 (B- cell lymphoma-leukemia 2) homologue, is known to function as an anti-apoptotic protein. Here we show in vitro and in vivo that MCL1 interacts with the cell cycle regulator, proliferating cell nuclear antigen (PCNA). This finding prompted us to investigate whether MCL1, in addition to its anti-apoptotic function, has an effect on cell cycle progression. A bromodeoxyuridine uptake assay showed that the overexpression of MCL1 significantly inhibited the cell cycle progression through the S-phase. The S-phase of the cell cycle is also known to be regulated by PCNA. A mutant of MCL1 that lacks PCNA binding (MCL1⌬4A) could not inhibit cell cycle progression as effectively as wild type MCL1. In contrast, MCL1⌬4A retained its anti-apoptotic function in HeLa cells when challenged by Etoposide. In addition, the intracellular localization of MCL1⌬4A was identical to that of wild type MCL1. An in vitro pull-down assay suggested that MCL1 is the only Bcl-2 family protein to interact with PCNA. In fact, MCL1, not other Bcl-2 family proteins, contained the PCNA-binding motif described previously. Taken together, MCL1 is a regulator of both apoptosis and cell cycle progression, and the cell cycle regulatory function of MCL1 is mediated through its interaction with PCNA.

Interaction between MCL1 and PCNA

EXPERIMENTAL PROCEDURES

Cell Lines—Transformed human embryonic kidney (293T) cells were purchased from the American Type Culture Collection (Manassas, VA). HeLa and U2OS cells (an osteosarcoma cell line) are generous gifts from Dr. Limin Gong (Institute of Molecular Medicine for Prevention of Human Diseases, Houston, TX). Cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum, nonessential amino acids, and antibiotics (Life Technologies, Inc.). Molecular Cloning—The cDNA fragments of MCL1, PCNA, Survivin, Bcl-xL, Bak, and Bax were obtained by a standard PCR technique (29) using appropriate primer sets. These cDNA fragments were then ligated in-frame to appropriate yeast and mammalian expression vectors. A mutant of MCL1, MCL1⌬4A, was generated by PCR-based strategies as described previously (30). In all cases, the authenticity of cloned constructs was confirmed by automated dideoxynucleotide sequencing (SeqWright Co., Houston, TX). Yeast Two-hybrid Library Screening—The full-length MCL1 was cloned into pAS2.1 (CLONTECH, Palo Alto, CA), a vector that encodes GAL4 DNA-binding domain, and was used as bait. Saccharomyces cerevisiae PJ69-2A cells (MATa, CLONTECH) were transformed with pAS2.1-MCL1, using the lithium acetate method (31). We then performed yeast mating between PJ69-2A cells containing pAS2.1-MCL1 and Y187 cells (MAT␣) containing a human HeLa cell library on pGAD GH (a vector that encodes GAL4 DNA-activating domain) for 27 h, according to the manufacturer’s instructions (31). Diploid yeast cells were selected for growth on synthetic dropout (SD) plates lacking adenine, histidine, leucine, and tryptophan (SD/⫺Ade/⫺His/⫺Leu/⫺Trp) for 14 days at 30 °C. Positive colonies were screened for ␤-galactosidase activity using a X-gal (5-bromo-4-chloro-3-indolyl ␤-D-galactopyranoside) filter lift assay (31). Plasmid DNAs were then isolated from colonies that activated all three yeast reporter genes (HIS3, ADE2, and lacZ) using the lyticase method (31), propagated in the Escherichia coli, and analyzed by restriction digest and automated dideoxynucleotide sequencing (SeqWright). Yeast Two-hybrid Assay—S. cerevisiae SFY526 cells (CLONTECH) were co-transformed with pAS2.1 containing full-length MCL1 or empty pAS2.1 and pGAD GH containing M01, the C-terminal half (137th to 261st amino acids) of PCNA or empty pGAD GH. Transformed cells were selected on SD/⫺Trp/⫺Leu plates for 7 days and subjected to the X-gal filter lift assay as described above. The blue color that developed within 8 h was considered to represent a positive interaction. In Vitro Binding Assay—Radiolabeled proteins for an in vitro binding assay were generated by a TNT Quick-coupled Transcription/Translation System (Promega, Madison, WI) according to the manufacturer’s instruction, using [35S]methionine (Amersham Pharmacia Biotech) as a labeling agent. DNA templates were either circular plasmids or gelpurified PCR products, containing a T7 RNA polymerase promoter. The in vitro translated, influenza hemagglutinin-tagged PCNA (HA-PCNA) and another in vitro translated protein were added to Buffer A (50 mM

HEPES, pH 7.5, 70 mM KCl, 0.5 mM ATP, 5 mM MgSO4, 1 mM dithiothreitol, 0.001% Nonidet P-40, 50 ␮M MG132, 2 ␮g/ml bovine serum albumin, aprotinin, phenylmethylsulfonyl fluoride, and protease inhibitor mixture (Sigma)) and allowed to form a complex at 4 °C for 90 min. HA-PCNA was then pulled down with rat anti-HA antibody (Clone 3F10, Roche Molecular Biochemicals) and sheep anti-rat polyclonal antibody conjugated to DynabeadsTM (M480, Dynal, Lake Success, NY). Immune complexes were then washed 5 times with Buffer A and once with Buffer B (Buffer A with 0.01% Nonidet P-40). Finally, precipitated proteins were eluted into SDS gel loading buffer (50 mM Tris䡠Cl, pH 6.8, 100 mM dithiothreitol, 2% SDS, 0.1% bromphenol blue, and 10% glycerol), boiled for 5 min, subjected to 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and visualized by fluorography and a PhosphorImager system (Bio-Rad). In Vivo Co-immunoprecipitation Assay of Overexpressed MCL1 and Native PCNA—The cDNA of MCL1 was cloned in-frame into EcoRI and PstI sites of pEGFP-C2 (CLONTECH) to express MCL1 fused to the C terminus of an enhanced green fluorescent protein (EGFP). Approximately 1 ⫻ 106 293T cells were transfected with pEGFP-MCL1 or empty pEGFP using LipofectAMINE PLUS (Life Technologies, Inc.). Forty hours after the transfection, the cells were harvested by trypsinization and lysed by a nitrogen cavitation method (32) (PARR Instrument Co, Moline, IL) in Buffer C (phosphate-buffered saline containing phenylmethylsulfonyl fluoride, aprotinin, and a mammalian cell protease inhibitor mixture (Sigma)). At least a pressure of 2000 pounds/square inch was applied. The disruption of both cell wall and nuclear membrane was confirmed under microscopy. The total cell lysate was cleared by centrifugation. An aliquot of approximately 2 ⫻ 105 cells was incubated either with anti-PCNA monoclonal antibody (PC-10, IgG2, PharMingen, San Diego, CA) or with anti-GFP monoclonal antibody (Clone 3E6, IgG1, Quantum Biotechnology Inc., Montreal, Canada). Formed immune complexes were then precipitated by sheep anti-mouse antibodies conjugated to DynabeadsTM (M-280, Dynal). The precipitated complexes were washed 6 times with cold Buffer C, eluted into SDS gel loading buffer, boiled for 5 min, and subjected to a 12% SDS-PAGE. After the Western transfer, proteins on the nitrocellulose membrane were probed with anti-PCNA (PC-10) and anti-GFP (Clones 7.1 and 13.1, both IgG1, Roche Molecular Biochemicals) monoclonal antibodies. Bound antibodies were detected using subtype-specific rabbit anti-mouse IgG antibodies (Southern Biotechnology Associates, Inc., Birmingham, AL) conjugated to horseradish peroxidase with the ECLTM detection system (Amersham Pharmacia Biotech). In Vivo Co-immunoprecipitation Assay of Native MCL1-PCNA Interaction—Approximately 2 ⫻ 107 HeLa cells were harvested by trypsinization and suspended in Buffer A. Cells were then mechanically disrupted by the nitrogen cavitation with a pressure of 3000 pounds/ square inch as described earlier. The cell lysate was cleared by centrifugation, and 500 ␮l of each was aliquoted into two tubes. Five micrograms of anti-PCNA monoclonal antibody (PC-10) were added to the first tube, and the same amount of control monoclonal antibody was added to the second tube. After incubation at 4 °C for 2 h, goat antimouse IgG conjugated to Dynabeads娂 (M-280, Dynal) was added to the tubes, followed by an incubation of 1 h. The beads were washed six times with Buffer A. Immune complexes were eluted into SDS gel loading buffer, boiled for 5 min, separated on 12% SDS-PAGE in duplicate, transferred to nitrocellulose membranes, immunoprobed with anti-PCNA (PC-10) and anti-MCL1 (Santa Cruz Biotechnology, Inc, Santa Cruz, CA) antibodies, and visualized by appropriate secondary antibodies conjugated to horseradish peroxidase (Southern Biotechnology Associates, Inc.) and the ECL detection system (Amersham Pharmacia Biotech). Indirect Immunofluorescence and Confocal Laser Scanning Microscopy—Immunofluorescence staining and confocal laser scanning microscopy was performed as described previously (33). In brief, U2OS cells were seeded in 4-well Lab-Teck娂 glass chamber slides (Nalge Nunc International, Rochester, NY). The cells were fixed with fresh 4% paraformaldehyde in phosphate-buffered saline, briefly treated with methanol/acetone mixture (1:1 v/v) at ⫺20 °C, blocked with 10% normal goat serum, and probed with rabbit anti-MCL1 polyclonal antibodies (Santa Cruz Biotechnology). Bound primary antibodies were detected by goat anti-rabbit antibody conjugated to Rhodamine Red X (Jackson ImmunoResearch Laboratories, West Grove, PA). Stained cells were analyzed with the Fluoview confocal laser scanning microscope (Olympus, Melville, NY), using the ⫻ 60 objective lens. The same analysis was performed to determine the intracellular localizations of overexpressed wild type and MCL1⌬4A, a mutant MCL1. Cell Death Assay—The experiment was performed in duplicate. HeLa cells were seeded in 4-well Lab-Teck娂 chamber slides, trans-


Bcl-2 homologous 3 subfamilies) (18). MCL1 (myeloid cell leukemia 1) is a 37.3-kDa protein originally cloned from a differentiating myeloid leukemia 1 cell line (19). Structurally and functionally, MCL1 belongs to the pro-survival Bcl-2 subfamily (20) that also includes Bcl-xL, Bcl-2, and Bcl-w (18). However, MCL1 possesses two unique features that make it outstanding among the pro-survival Bcl-2 subfamily proteins. First, MCL1 is inducible upon proliferative (21) and differentiating (19) stimuli. Second, the half-life of MCL1 is short (19, 21) most likely because MCL1 contains two PEST sequences (22). These PEST sequences are not present in other Bcl-2 family proteins (19). Interestingly, the PEST sequence is present in a number of cell cycle proteins, including cyclin D1, E (23), G2 (24), F (25), I (26) and c-Fos (27). In order to investigate the mechanism of action and the potentially undiscovered functions of MCL1, we screened a human HeLa cell library with a yeast two-hybrid system using MCL1 as bait. Here we report a specific interaction between MCL1, an anti-apoptotic protein and a cell cycle regulatory protein, PCNA (28). In this report, we propose that MCL1 is not only an anti-apoptotic protein but also a cell cycle regulator and that the cell cycle regulatory function of MCL1 is at least partially mediated through its interaction with PCNA.

39459

39460


RESULTS

MCL1 Specifically Interacts with PCNA—In order to identify the protein(s) interacting with MCL1, we screened a human HeLa cell cDNA library using the yeast two-hybrid system. Among the 2 ⫻ 106 independent clones screened, one clone, named “M01,” not only grew on histidine-adenine dropout plates but also activated the ␤-galactosidase reporter gene by an X-gal colony lift assay. A DNA sequence analysis revealed that the clone M01 represents the C-terminal 124 amino acid residues of human PCNA, which is fused in frame to the GAL4 activation domain (Fig. 1A). The presence of both MCL1 and M01 was necessary and sufficient for ␤-galactosidase reporter gene to be activated in yeast SFY526 cells (Fig. 1A). Thus, we concluded that MCL1 specifically interacted with the C-terminal half of PCNA in the yeast two-hybrid system. We then performed an in vitro co-immunoprecipitation assay to test whether MCL1 would interact with the full-length PCNA. Here, we incubated in vitro translated, radiolabeled, influenza hemagglutinin (HA)-tagged PCNA with either in vitro translated, radiolabeled MCL1 or Survivin. Survivin is a member of inhibitor of apoptosis protein family, another antiapoptotic protein family structurally unrelated to Bcl-2 family proteins (14, 15). As is shown in Fig. 1B, PCNA co-precipitated MCL1 (lanes 1 and 5) but not Survivin (lanes 2 and 6). Moreover, MCL1 could not be precipitated in the absence of PCNA (lanes 3 and 7). Thus, MCL1 specifically interacted with fulllength PCNA in vitro. We proceeded to test if MCL1 would interact with PCNA in mammalian cells in vivo. We transfected human embryonic kidney 293T cells with a plasmid encoding the cDNA of either the EGFP-tagged MCL1 or EGFP alone. As a result, EGFPMCL1 and EGFP were found plentifully expressed in 293T cells (Fig. 1C, lanes 1 and 2, top panel). On the other hand,

PCNA was found abundantly expressed in these cells without forced overexpression (Fig. 1C, lanes 1 and 2, bottom panel). When we immunoprecipitated PCNA in the cell lysate by an anti-PCNA antibody (lanes 3 and 4, bottle panel), only EGFPMCL1, not EGFP, was co-immunoprecipitated with PCNA (lanes 3 and 4, top panel). When we immunoprecipitated EGFP or EGFP-MCL1 in the cell lysate by anti-EGFP antibody (lanes 5 and 6, top panel), only EGFP-MCL1, but not EGFP, coimmunoprecipitated PCNA (lanes 5 and 6, bottom panel). Thus, MCL1 specifically interacted with PCNA in mammalian cells in vivo. So far we have shown that MCL1 and PCNA interacted specifically with each other in overexpression systems (Fig. 1, A–C). We wished to evaluate whether this interaction could be demonstrated in a non-overexpression, native system. To this end, the lysate from 2 ⫻ 107 HeLa cells was incubated with anti-PCNA antibody or with control antibody at the same concentration. As is shown in Fig. 1D, the lysate contained an equal amount of native MCL1 and PCNA as is shown in the bottom two panels (Total Cell Lysate (Input)). When the precipitated immune complexes were probed with anti-PCNA antibody, PCNA was found successfully precipitated by anti-PCNA antibody but not by the control antibody (Fig. 1D, 2nd panel). When the immune complexes were probed with anti-MCL1 antibody, MCL1 was found co-precipitated with PCNA (Fig. 1D, top panel, 1st column). There was no MCL1 precipitated in the absence of PCNA (Fig. 1D, top panel, 2nd column). This result strongly suggests that MCL1-PCNA interaction is biologically significant since it can be demonstrated in native, non-overexpression system as well as an overexpression system. MCL1 Is Unique Among Bcl-2 Family Member Proteins in Its Ability to Interact Specifically with PCNA—We then evaluated whether PCNA interacted with other Bcl-2 family proteins. By using the same system as the one described in Fig. 1B, we tested the ability of PCNA to co-precipitate other pro- and anti-apoptotic Bcl-2 family proteins including Bcl-xL, Bak, or Bax. As is shown in Fig. 2, PCNA co-precipitated only MCL1 and not Bcl-xL, Bak, or Bax. Thus, MCL1 is an unusual Bcl-2 family protein that is capable of interacting with PCNA, a cell cycle regulatory protein. MCL1 Is Present in the Nuclei and Cytosol—Functionally, PCNA serves as a cofactor to DNA polymerase ␦ (34) and modulates the function of other nuclear proteins, such as RF-C (Replication Factor-C) and Fen-I (35–37). Previous immunocytochemical studies further support that the functional site of action of PCNA is the nucleus (38). The biochemical evidence that we presented showed the presence of specific interaction between MCL1 and PCNA. We wished to determine the intracellular localization of MCL1. We proceeded to perform immunocytochemical staining of native MCL1 in U2OS cells. The cross-sectional analysis of the stained U2OS cells by confocal microscopy showed that MCL1 was both in the cytosol and nucleus, the nucleus being the predominant location (Fig. 3a). No confocal signals were detected when primary antibodies were omitted (Fig. 3b). Since PCNA is localized in the nucleus (38), the current data suggest that MCL1 is capable of physically interacting with PCNA in the nucleus. MCL1 Contains a Conserved PCNA-binding Motif, a Mutation of Which Abolishes Its Binding to PCNA—Most of the previously identified PCNA-binding proteins contain a certain conserved amino acid motif (Fig. 4A) (36, 37, 39 – 45). The motif normally consists of a glutamine residue and a phenylalanine residue separated by 6 amino acid residues (Xs), QX1– 6F. Uniformly, this motif is followed by a region rich in basic amino acids and lysine in particular, which is implicated for sub-


fected either with pFLAG-MCL1, pFLAG-MCL1⌬4A, or pFLAG-LacZ using FuGENE6 (Roche Molecular Biochemicals), challenged with 5 ␮g/ml Etoposide for 12 h, and stained for the FLAG epitope using anti-FLAG antibody (M2, Sigma) and anti-mouse IgG conjugated to Rhodamine Red X (Jackson ImmunoResearch Laboratories). The nuclei were stained with DAPI (4,6-diamidino-2-phenylindole, Sigma). Cells were then examined under a Zeiss Axioskop fluorescent microscope (Carl Zeiss Ltd, Herts, UK), using appropriate filter sets. Cells that emitted red fluorescence were evaluated for their nuclear morphology. The condensed or fragmented nuclei were counted as apoptotic. An apoptotic index was then calculated as the number of red cells with apoptotic nuclear morphology divided by the number of total red cells counted. Bromodeoxyuridine (BrdUrd) Uptake Assay—This experiment was performed in duplicate. Approximately 10,000 HeLa cells were seeded in 4-well Lab-Teck娂 chamber slides (Nalge Nunc International). The next day, cells were transfected with pFLAG-LacZ, pFLAG-p21Waf1/Cip1, pFLAG-MCL1, or pFLAG-MCL1⌬4A using FuGENE6 (Roche Molecular Biochemicals) according to manufacturer’s instruction. Cells were exposed to DNA-FuGENE6 complex for 5 h. Eighteen hours after the media change, cells were pulsed with 50 ␮M BrdUrd solution for 30 min at 37 °C. Harvested cells were first stained for incorporated BrdUrd, using a BrdUrd staining kit (Roche Molecular Biochemicals). In this procedure, bound anti-BrdUrd antibody was detected by goat antimouse Rhodamine Red X antibody (Jackson ImmunoResearch Laboratories). Cells were then stained for FLAG-tagged proteins with rabbit anti-FLAG antibody (Zymed Laboratories Inc., South San Francisco, CA) and goat anti-Rabbit-Cy2 antibody. The nuclei were counterstained with DAPI. The slides were examined under the Zeiss Axioskop fluorescent microscope (Carl Zeiss Ltd.), using appropriate filter sets. At least 150 cells (average ⫽ 364) were counted per chamber. The BrdUrd incorporation was defined as the number of green cells with red nuclei (FLAG- and BrdUrd-positive) divided by the number of green cells (FLAG-positive). Statistical Analysis—Statistical analysis was performed using a generalized linear model with Duncan multiple comparison at the significance level of 0.05.


39461

nuclear targeting (Fig. 4A, underlined K) (35). In some PCNAbinding proteins, disruption of this motif is shown to abolish their PCNA binding capacity (35, 40, 41). We evaluated whether MCL1, which was capable of binding PCNA, had the

same consensus sequence. The protein sequence analysis of MCL1 and its mouse counterpart EAT revealed that both proteins in fact contained a conserved amino acid motif, i.e. 221 QRNHETAF228 sequence followed by lysine-rich regions


FIG. 1. MCL1 specifically interacts with PCNA in yeast, in vitro and in vivo. A, yeast two-hybrid assay. S. cerevisiae SFY526 cells were co-transformed with pAS2.1 or pAS2.1-MCL1 and pGAD GH or pGAD GH-M01, the C-terminal half (137th to 261st amino acids) of PCNA. Transformed cells were selected on SD/⫺Trp/⫺Leu plates. Grown colonies on these selection plates were subjected to a X-gal filter lift assay. ⫺, no blue color on the X-gal filter lift assay; ⫹, blue color on the X-gal filter lift assay within 8 h. The upper panel shows the domain structures of MCL1 and PCNA. MCL1 consists of four Bcl-2 homologous domains and two PEST sequences. CHT denotes the C-terminal hydrophobic tail. PCNA consists of two major domains homologous to each other, domain 1 and domain 2. B, in vitro binding assay. The in vitro translated, [35S]Met-labeled influenza hemagglutinin-tagged PCNA (HA-PCNA) and another in vitro translated, [35S]Met-labeled protein, as indicated in the figure, were incubated at 4 °C for 90 min. HA-PCNA was then pulled down with rat anti-HA monoclonal antibody (mAb) and sheep anti-rat polyclonal antibody conjugated to DynabeadsTM (Dynal). Immune complexes were extensively washed, subjected to SDS-PAGE, and visualized by fluorography and a PhosphorImager system. Input represents 1/10 of the proteins in volume added to the immunoprecipitation (IP) reaction. MCL1 (lanes 1 and 5), not Survivin (lanes 2 and 6), was co-immunoprecipitated with PCNA in vitro. C, in vivo co-immunoprecipitation assay. 293T cells were transfected with pEGFP-MCL1 or empty pEGFP and subsequently lysed by the nitrogen cavitation method. The lysates were then cleared by centrifugation. An aliquot was incubated either with anti-PCNA monoclonal antibody (IP-1, lanes 3 and 4) or anti-GFP (IP-2, lanes 5 and 6) monoclonal antibody. Formed immune complexes were then precipitated by sheep anti-mouse antibodies conjugated to DynabeadsTM. The precipitated complexes were washed extensively and subjected to SDS-PAGE, Western transfer, and immunodetection with anti-PCNA (lower panel) and anti-GFP (upper panel) monoclonal antibodies. Total cell lysate (TCL) (Input, lanes 1 and 2) contained adequate amounts of native PCNA and ectopically expressed GFP-MCL1 or GFP. PCNA co-immunoprecipitated GFP-MCL1 but not GFP (lanes 3 and 4). GFP-MCL1, but not GFP, co-immunoprecipitated PCNA (lanes 5 and 6). D, in vivo co-immunoprecipitation assay of native MCL1 and PCNA. The total cell lysates from 2 ⫻ 107 HeLa cells were incubated either with anti-PCNA monoclonal antibody (PC-10) or a control monoclonal antibody. After a 2-h incubation, goat anti-mouse IgG conjugated to DynabeadsTM was added, and the mixtures were incubated for an additional 1 h. After extensive wash, the precipitated complexes were eluted to SDS gel loading buffer, separated on 12% SDS-PAGE, and subjected to Western blotting and immunoprobing with anti-PCNA and anti-MCL1 antibodies. Total cell lysates contained abundant amounts of MCL1 and PCNA (bottom two panels). PCNA was successfully immunoprecipitated by anti-PCNA antibody but not by control antibody (2nd panel). MCL1 was co-precipitated only in the presence of immunoprecipitated PCNA (top panel).

39462


FIG. 2. MCL1 is unique among Bcl-2 family member proteins in its ability to interact with PCNA. The binding between in vitro translated, [35S]Met-labeled HA-PCNA and another in vitro translated, [35S]Met-labeled protein (i.e. MCL1, Bcl-xL, Bak, or Bax) was assessed in the system described in Fig. 1B. Only MCL1 (lanes 1 and 6) and not Bcl-xL (lanes 2 and 7), Bak (lanes 3 and 8), or Bax (lanes 4 and 9) was co-immunoprecipitated with PCNA in vitro.

(Fig. 4A). We could not find this motif in Bcl-xL, Bak, or Bax, which is consistent with the fact that Bcl-xL, Bak, or Bax did not bind to PCNA (Fig. 2). We then tested if this QX1– 6F motif, representing the 221st to 228th amino acids of MCL1, is critical for the MCL1-PCNA interaction. We constructed an MCL1 mutant MCL1⌬4A in which four amino acids (His224, Glu225, Thr226, and Phe228) within this motif were replaced with alanines (Fig. 4A, bottom row). We first tested if MCL1⌬4A would interact with PCNA, by using the same system as the one shown in Fig. 1B and Fig. 2. In this system (Fig. 4B), wild type MCL1 was again demonstrated to interact with PCNA (Fig. 4B, lanes 1 and 7). In addition, Bcl-xL was again shown not to interact with PCNA (Fig. 4B, lanes 3 and 9). The p21Waf1/Cip1 known to interact with PCNA (39) was co-precipitated by PCNA (Fig. 4B, lanes 4 and 10). As we suspected, MCL1⌬4A failed to interact with PCNA in this system (Fig. 4B, lanes 2 and 8). Therefore, QX1– 6F motif within MCL1 is necessary for the MCL1-PCNA interaction to occur. We proceeded to evaluate the intracellular localization of the MCL1⌬4A in comparison with that of the wild type MCL1. The FLAG epitope-tagged wild type MCL1 or MCL1⌬4A was overexpressed in U2OS cells. Their intracellular localizations were then evaluated by immunostaining with anti-FLAG antibody. As is shown in Fig. 4C, both wild type and mutant MCL1 localized predominantly in the nuclear and perinuclear regions


FIG. 3. MCL1 is present in the nuclei by confocal microscopy in U2OS cells. For the intracellular localization of MCL1, U2OS cells seeded on glass chamber slides were fixed with 4% paraformaldehyde in phosphate-buffered saline, treated with methanol/acetone mixture at ⫺20 °C, and probed either with anti-MCL1 polyclonal antibody (a) or with staining buffer only (negative control; b). Bound antibodies were detected by goat anti-rabbit antibody conjugated to Rhodamine Red X. Stained cells were analyzed with the Olympus Fluoview (⫻ 60 objective) confocal laser scanning microscope. Confocal signals are most prominent in the nucleus in U2OS cells. Faint signals were observed in the cytosol.

by confocal microscopy. We concluded that the mutation introduced within the region of the QX1– 6F motif of MCL1 did not alter its intracellular localization. Finally, we tested whether MCL1⌬4A retained anti-apoptotic function like wild type MCL1. To this end, HeLa cells overexpressing FLAG-tagged wild type MCL1, MCL1⌬4A, or ␤-galactosidase (LacZ) were challenged with etoposide, a topoisomerase II inhibitor, to induce apoptosis. Twelve hours after the challenge, cells were stained with anti-FLAG antibody and DAPI. The cells positively stained with anti-FLAG antibody were examined for their nuclear morphology visualized by DAPI. Strikingly, MCL1⌬4A, a MCL1 mutant that lacks PCNA binding, and the wild type MCL1 equally prevented etoposide-induced apoptosis in HeLa cells (Fig. 4D). This observation is important in several aspects. First, the interaction of MCL1 with PCNA was not necessary for MCL1 to function as an anti-apoptotic protein. Second, the mutation introduced to the PCNA-binding motif of MCL1, 221 QRNHETAF228, did not abolish the anti-apoptotic function of MCL1. Thus, MCL1 exerts its anti-apoptotic function through a different region than the 221QRNHETAF228. Finally, the ability for MCL1 to distribute both in cytosol and nucleus is conferred by different region(s) of MCL1 than the 221QRNHETAF228 since intracellular distribution of MCL1⌬4A was similar to that of the wild type as is shown in Fig. 4C. MCL1 Overexpression Decreases BrdUrd Uptake in HeLa Cells—PCNA was originally isolated as a protein that appeared in elevated levels during the S-phase (34). In addition, the expression of PCNA antisense mRNA in proliferating cells causes the suppression of DNA replication and the cell cycle arrest at the S-phase (46). Moreover, PCNA functions as the processivity factor for DNA polymerase ␦ (34) and as a stimulatory factor of FEN-1, a protein that is involved in the maturation of an Okazaki fragment during DNA synthesis (37). PCNA-staining patterns co-localize with areas of radioactive thymidine uptake (47) or staining for BrdUrd (48). Our data showed the presence of specific interaction between MCL1 and PCNA and indicated that the interaction occurs in the nucleus. In addition, we showed above that MCL1-PCNA interaction is not required for the anti-apoptotic function of MCL1. Thus, we speculated that the MCL1-PCNA interaction might contribute to a certain function other than apoptosis regulation. Based on the role of PCNA in the S-phase progression, we hypothesized that MCL1, by binding to PCNA, affects the function of PCNA as an S-phase protein. Accordingly, we evaluated the effect of MCL1 overexpression on DNA synthesis in HeLa cells, using BrdUrd uptake as an indicator of DNA synthesis (Fig. 5, a– c). As is shown in Fig. 5d, 34.1% of the cells transfected with the ␤-galactosidase gene (lacZ, a control gene) took up BrdUrd during the 30-min pulse-labeling time with BrdUrd. When p21Waf1/Cip1 was overexpressed, none of the cells took up BrdUrd during this time, which was consistent with previous reports. The p21Waf1/Cip1 is shown to bind PCNA, interfering with its interaction with DNA polymerase ␦ (39). The p21Waf1/Cip1 also binds and inactivates CDKs. Inactivation of CDKs increases the unphosphorylated retinoblastoma gene products, which sequester E2F, a transcriptional factor for the transactivation of S-phase genes (9 –11). In this system, MCL1 overexpression was associated with the 63.3% reduction of cells that took up BrdUrd as compared with the control (12.5 ⫾ 1.2% for MCL1 versus 34.1 ⫾ 3.5% for LacZ, Fig. 5d). Thus, MCL1 is a dual function protein with the anti-apoptotic and S-phase inhibitory functions. The Lack of PCNA Binding (MCL1⌬4A) Attenuates the Inhibitory Effect of MCL1 on DNA Synthesis—In the same experi-


39463

ment, cells transfected with MCL1⌬4A synthesized 82% more DNA (22.75 ⫾ 2.5%) than cells transfected with wild type MCL1 (12.5 ⫾ 1.2%, significant at 0.05 level; Fig. 5d). Since MCL1⌬4A lacks the capability of binding to PCNA, the relative inefficiency of MCL1⌬4A to suppress DNA synthesis indicates that MCL1 interferes with S-phase DNA synthesis at least partially through its interaction with PCNA. Thus, the interaction of MCL1 with PCNA mediates the cell cycle regulatory function but not the anti-apoptotic function of MCL1. The exact mechanism by which MCL1 interferes with PCNA-dependent DNA synthesis requires further investigation.

DISCUSSION

We showed that MCL1 physically and functionally interacts with PCNA (Fig. 1). This MCL1-PCNA interaction is unique because PCNA interacts only with MCL1 and not with other Bcl-2 family member proteins (Fig. 2). The functional significance of the MCL1-PCNA interaction may be that MCL1 interferes with the cell cycle progression through its binding to PCNA (Fig. 5). To our knowledge, the presence of the physical and functional interaction between MCL1 and PCNA has not been reported in literature. The current data also support that


FIG. 4. Characterization of an MCL1 mutant (MCL1⌬4A). A, protein sequence alignment of MCL1 and EAT (mouse MCL1) with other PCNA-binding proteins. The computer-assisted alignment of MCL1, EAT, and other PCNA-binding proteins showed that the characteristic PCNA-binding motif QX1– 6F exists in MCL1, EAT, and nearly all the PCNA-binding proteins. AA denotes the position of the starting amino acid residues. Black boxes represent identical amino acid residues of previously described PCNA-binding proteins to those of MCL1. Shaded boxes represent homologous amino acid residues to those of MCL1. Lysine residues following QX1– 6F motif are underlined. An asterisk shows the best aligned motif among four putative QX1– 6F motifs present in MSH2. A MCL1 mutant MCL1⌬4A contains 4 amino acid substitutions (indicated by a caret) within the QX1– 6F motif (the bottom row). B, an in vitro binding assay between PCNA and a MCL1 mutant MCL1⌬4A. The binding between in vitro translated, [35S]Met-labeled HA-PCNA and another in vitro translated, [35S]Met-labeled protein, including MCL1 and a MCL1 mutant (MCL1⌬4A), was evaluated in the system described in Fig. 1B. Only wild type MCL1 (lanes 1 and 7), not MCL1⌬4A (lanes 2 and 8), was co-immunoprecipitated with PCNA in vitro. Bcl-xL was used as negative control (lanes 3 and 9), whereas p21Waf1/Cip1, a known PCNA-binding protein, was used as positive control (lanes 4 and 10). C, intracellular localization of wild type and mutant MCL1 (MCL1⌬4A) in U2OS cells. U2OS cells were transfected with a mammalian expression vector encoding the cDNA of either FLAG-tagged MCL1 or MCL1⌬4A and stained with anti-FLAG monoclonal antibody (M2, Sigma) and goat anti-mouse IgG conjugated to Rhodamine Red X. Confocal microscopic analysis showed the similar intracellular localization of both wild type and MCL1⌬4A. D, anti-apoptotic effect of wild type and a mutant MCL1 (MCL1⌬4A) in HeLa cells. HeLa cells were transfected with a mammalian expression plasmid encoding the cDNA of either FLAG-tagged wild type MCL1 or its mutant MCL1⌬4A. Cells were then challenged by etoposide (5 ␮g/ml) for 12 h, stained with anti-FLAG monoclonal antibody (M2) and goat anti-mouse IgG conjugated to Rhodamine Red X and DAPI, and evaluated under fluorescence microscope with Rhodamine Red filter sets. Cells that emit red fluorescence were then evaluated for their nuclear morphology using DAPI filter sets. The nuclei that are condensed or fragmented were counted as apoptotic. The apoptotic index was calculated as the number of red cells with apoptotic nuclei divided by the number of total red cells counted. Both wild type MCL1 and MCL1⌬4A prevented HeLa cells from undergoing etoposide-induced apoptosis. NS, not statistically different.

39464


MCL1 is another example of regulatory molecules that interface between apoptosis and cell cycle progression, like p53, E25, and Survivin (see Introduction). Moreover, MCL1 appears to use different regions within the molecule to mediate two distinct functions, anti-apoptosis and cell cycle regulatory functions (Figs. 4 and 5). PCNA plays a critical role in DNA replication. During DNA replication, PCNA first forms a complex with RF-C, a large nuclear complex, which allows PCNA to assemble into a trimer, the functional form of PCNA (28). The RF-C-PCNA complex then binds to the RNA priming site, allowing DNA polymerase ␦ to bind PCNA and initiate DNA replication (49). In the current study, we demonstrated that the overexpression of MCL1 decreased BrdUrd uptake in a PCNA-dependent fashion (Fig. 5). One of the possible mechanisms to explain this is that MCL1 binds PCNA and prevents PCNA from physically associating with RF-C or with DNA polymerase ␦. This can be through simple physical interference or through induced conformational changes within PCNA. The end result of this binding would be the inhibition of DNA synthesis and reduction of BrdUrd uptake, consistent with our findings described in this paper (Fig. 5). The MCL1⌬4A did not completely reverse the inhibitory effect of MCL1 on DNA synthesis (Fig. 5d). One of the possibilities to explain this is that there may be still another pathway through which MCL1 inhibits DNA synthesis. This is true in the case of p21, which inhibits DNA synthesis not only by binding to PCNA (39, 51) but also by binding to the CDKs (50). Another possibility is that MCL1⌬4A retains weak binding to PCNA in a certain microenvironment in vivo. This possibility is still consistent with the in vitro finding described earlier in Fig. 4B, where stringent washing was performed after PCNA and MCL1⌬4A were allowed to interact. The PCNA-binding motif QX1– 6F of MCL1 may be one, but not all, of the regions that

participate in its binding to PCNA. The mutation we introduced to generate MCL1⌬4A may well have significantly reduced, but not completely abolished, its binding to PCNA. Crystallographic analysis of MCL1 and PCNA would be extremely helpful in identifying all the regions of MCL1 that participate in the PCNA binding. Among a number of mechanisms that regulate cellular DNA synthesis, the p53-p21Waf1/Cip1 pathway is one of the best studied. The DNA-damaging stimuli result in up-regulated p53 expression, which in turn transcriptionally activates p21Waf1/ Waf1/Cip1 Cip1 expression (45). Induced p21 in turn binds to and inhibits CDKs, causing hypophosphorylation of Retino Rastoma gene product, sequestering E2F, and interfering with transcriptional activation of S-phase genes by E2F, thus blocking the G1-S transition (50). At the same time, p21Waf1/Cip1 also binds to PCNA and interferes with the binding of PCNA to DNA polymerase ␦. Since DNA polymerase ␦ requires PCNA to synthesize DNA effectively, the presence of p21Waf1/Cip1 inhibts DNA synthesis, thereby further retarding cell cycle progression (39, 51). The dual actions of p21Waf1/Cip1 on cell cycle progression may explain why p21Waf1/Cip1 inhibited BrdUrd uptake more completely than MCL1 (Fig. 5d). Although not tested in the current work, it is possible that MCL1 does not have effects on CDKs activities and that transactivation of S-phase genes by E2F occurs normally in the presence of MCL1. Nevertheless, the current finding that MCL1 binds PCNA and interferes with BrdUrd uptake (Fig. 1 and Fig. 5) indicates that MCL1 may represent a novel regulatory mechanism of PCNA-dependent DNA synthesis. In our view, the significance of our current data is that we showed MCL1 is a dual function protein with anti-apoptotic and anti-PCNA function; the latter is mediated by its physical interaction with PCNA. In addition, it is likely that MCL1 uses different regions within the molecule to mediate these two


FIG. 5. Overexpression of MCL1 decreases BrdUrd uptake in HeLa cells. HeLa cells were seeded in a 4-well Lab-Teck娂 chamber slide and transfected with pFLAG-LacZ, pFLAG- p21Waf1/Cip1, pFLAG-MCL1, or pFLAG- MCL1⌬4A. Eighteen hours after the media change, cells were pulsed with 50 ␮M BrdUrd solution for 30 min, harvested, and stained for FLAG-tagged proteins and for incorporated BrdUrd. Then, Cy2- (a) and Rhodamine Red X (b)-conjugated secondary antibodies were used to detect bound primary antibodies, respectively. The nuclei were counterstained with DAPI (c). The numbers on the cells in c represent the following: 1, the FLAG epitope-positive cell with BrdUrd uptake; 2, the FLAG epitope-positive cell without BrdUrd uptake; 3, the FLAG epitope-negative cell with BrdUrd uptake; 4, the FLAG epitope-negative cell without BrdUrd uptake. The BrdUrd incorporation was defined as the number of green cells with red nuclei (FLAG- and BrdUrd-positive) divided by the number of green cells (FLAG-positive) (d). Statistical analysis performed using generalized linear model with Duncan multiple comparison with a significance level at 0.05 showed that the means of all four groups are statistically significantly different from each other. The overexpression of wild type MCL1 significantly reduced the fraction of the cells that synthesized DNA, whereas the overexpression of MCL1⌬4A, a mutant MCL1 that lacks PCNA binding, significantly attenuated that effect (*).

Interaction between MCL1 and PCNA distinct functions. The dual function of MCL1 may be beneficial in cells placed under certain conditions. For example, MCL1 is shown to be transiently up-regulated when cells sustain DNA damage (52). In this instance, up-regulated MCL1 may arrest the cell cycle progression through its interaction with PCNA, thus preventing these cells from replicating altered DNAs. At the same time, MCL1 may exert its anti-apoptotic function and ensure the survival of the cells until DNA repair is completed. Although the biological significance of the interplay between MCL1 and p21Waf1/Cip1, both of which are up-regulated in cells with genetic damage (45, 52), remains to be elucidated, this apparent redundancy may well represent still another safety mechanism by which living organisms increase their chance of survival under diverse environmental stresses. Acknowledgments—We thank Rebecca Higham and Tera Hallahan for their excellent technical support. We are grateful to Dr. James T. Willerson and the late Dr. Hans J. Mu¨ller-Eberhard for their inspiration, support, and encouragement. REFERENCES

430 – 436 21. Iyer, V. R., Eisen, M. B., Ross, D. T., Schuler, G., Moore, T., Lee, J. C. F., Trent, J. M., Staudt, L. M., Hudson, J., Jr., Boguski, M. S., Lashkari, D., Shalon, D., Botstein, D., and Brown, P. O. (1999) Science 283, 83– 87 22. Rogers, S., Wells, R., and Rechsteiner, M. (1986) Science 234, 364 –368 23. Langenfeld, J., Kiyokawa, H., Sekula, D., Boyle, J., and Dmitrovsky, E. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12070 –12074 24. Horne, M. C., Goolsby, G. L., Donaldson, K. L., Tran, D., Neubauer, M., and Wahl, A. F. (1996) J. Biol. Chem. 271, 6050 – 6061 25. Bai, C., Richman, R., and Elledge, S. J. (1994) EMBO J. 13, 6087– 6098 26. Nakamura, T., Sanokawa, R., Sasaki, Y. F., Ayusawa, D., Oishi, M., and Mori, N. (1995) Exp. Cell Res. 221, 534 –542 27. Tsurumi, C., Ishida, N., Tamura, T., Kakizuka, A., Nishida, E., Okumura, E., Kishimoto, T., Inagaki, M., Okazaki, K., Sagata, N., Ichihara, A., and Tanaka, K. (1995) Mol. Cell. Biol. 15, 5682–5687 28. Kelman, Z. (1997) Oncogene 14, 629 – 640 29. Ausubel, F., Brent, R., Kingston, R., Moore, D., Seidman, J., Smith, J., and Struhl, K. (1998) in Current Protocols in Molecular Biology (Chanda, V. B., ed) unit 15.1, John Wiley & Sons, Inc., New York 30. Gong, L., Kamitani, T., Fujise, K., Caskey, L. S., and Yeh, E. T. (1997) J. Biol. Chem. 272, 28198 –28201 31. CLONTECH (1997) Yeast Handbook, pp. 30 –34, CLONTECH, Palo Alto, CA 32. Eichinger, L., Bahler, M., Dietz, M., Eckerskorn, C., and Schleicher, M. (1998) J. Biol. Chem. 273, 12952–12959 33. Liu, J. L., Ye, Y., Qian, Z., Qian, Y., Templeton, D. J., Lee, L. F., and Kung, H. J. (1999) J. Virol. 73, 4208 – 4219 34. Bravo, R., Frank, R., Blundell, P. A., and Macdonald-Bravo, H. (1987) Nature 326, 515–517 35. Montecucco, A., Rossi, R., Levin, D. S., Gary, R., Park, M. S., Motycka, T. A., Ciarrocchi, G., Villa, A., Biamonti, G., and Tomkinson, A. E. (1998) EMBO J. 17, 3786 –3795 36. Jonsson, Z., Hindges, R., and Hubscher, U. (1998) EMBO J. 17, 2412–2425 37. Li, X., Li, J., Harrington, J., Lieber, M. R., and Burgers, P. M. (1995) J. Biol. Chem. 270, 22109 –22112 38. Muro, Y., Tsai, W. M., Houghten, R., and Tan, E. M. (1994) J. Biol. Chem. 269, 18529 –18534 39. Waga, S., Hannon, G. J., Beach, D., and Stillman, B. (1994) Nature 369, 574 –578 40. Chuang, L. S., Ian, H. I., Koh, T. W., Ng, H. H., Xu, G., and Li, B. F. (1997) Science 277, 1996 –2000 41. Gary, R., Ludwig, D. L., Cornelius, H. L., MacInnes, M. A., and Park, M. S. (1997) J. Biol. Chem. 272, 24522–24529 42. Levin, D. S., Bai, W., Yao, N., O’Donnell, M., and Tomkinson, A. E. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12863–12868 43. Tsurimoto, T., and Stillman, B. (1991) J. Biol. Chem. 266, 1950 –1960 44. Umar, A., Buermeyer, A. B., Simon, J. A., Thomas, D. C., Clark, A. B., Liskay, R. M., and Kunkel, T. A. (1996) Cell 87, 65–73 45. Xiong, Y., Zhang, H., and Beach, D. (1992) Cell 71, 505–514 46. Jaskulski, D., deRiel, J. K., Mercer, W. E., Calabretta, B., and Baserga, R. (1988) Science 240, 1544 –1546 47. Bravo, R. (1986) Exp. Cell Res. 163, 287–293 48. Bravo, R., and Macdonald-Bravo, H. (1987) J. Cell Biol. 105, 1549 –1554 49. Jiang, Y., Zhang, S. J., Wu, S. M., and Lee, M. Y. (1995) Arch. Biochem. Biophys. 320, 297–304 50. Agarwal, M. L., Taylor, W. R., Chernov, M. V., Chernova, O. B., and Stark, G. R. (1998) J. Biol. Chem. 273, 1– 4 51. Bambara, R. A., Murante, R. S., and Henricksen, L. A. (1997) J. Biol. Chem. 272, 4647– 4650 52. Zhan, Q., Bieszczad, C. K., Bae, I., Fornace, A. J., Jr., and Craig, R. W. (1997) Oncogene 14, 1031–1039


1. Levine, A. J. (1997) Cell 88, 323–331 2. Miyashita, T., and Reed, J. C. (1995) Cell 80, 293–299 3. Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., and Tanaka, N. (2000) Science 288, 1053–1058 4. Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W. W., Kruzel, E., and Radinsky, R. (1995) Mol. Cell. Biol. 15, 3032–3040 5. Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., and Vogelstein, B. (1997) Nature 389, 300 –305 6. Wang, Y., and Prives, C. (1995) Nature 376, 88 –91 7. Field, S., Tsai, F., Kuo, F., Zubiaga, A., Kaelin, W., Jr., Livingston, D., Orkin, S., and Greenberg, M. (1996) Cell 85, 549 –561 8. Weinberg, R. A. (1995) Cell 81, 323–330 9. Hiebert, S. W., Lipp, M., and Nevins, J. R. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 3594 –3598 10. Sala, A., Nicolaides, N. C., Engelhard, A., Bellon, T., Lawe, D. C., Arnold, A., Grana, X., Giordano, A., and Calabretta, B. (1994) Cancer Res. 54, 1402–1406 11. DeGregori, J., Kowalik, T., and Nevins, J. R. (1995) Mol. Cell. Biol. 15, 4215– 4224 12. Blake, M. C., and Azizkhan, J. C. (1989) Mol. Cell. Biol. 9, 4994 –5002 13. Dou, Q. P., Markell, P. J., and Pardee, A. B. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3256 –3260 14. Ambrosini, G., Adida, C., and Altieri, D. C. (1997) Nat. Med. 3, 917–921 15. Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., and Altieri, D. C. (1998) Nature 396, 580 –584 16. Cleary, M. L., Smith, S. D., and Sklar, J. (1986) Cell 47, 19 –28 17. Chinnaiyan, A. M., O’Rourke, K., Lane, B. R., and Dixit, V. M. (1997) Science 275, 1122–1226 18. Adams, J. M., and Cory, S. (1998) Science 281, 1322–1326 19. Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., and Craig, R. W. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3516 –3520 20. Reynolds, J. E., Li, J., Craig, R. W., and Eastman, A. (1996) Exp. Cell Res. 225,

39465

MECHANISMS OF SIGNAL TRANSDUCTION: Regulation of Apoptosis and Cell Cycle Progression by MCL1: DIFFERENTIAL ROLE OF PROLIFERATING CELL NUCLEAR ANTIGEN Kenichi Fujise, Di Zhang, Juinn-lin Liu and Edward T. H. Yeh J. Biol. Chem. 2000, 275:39458-39465. doi: 10.1074/jbc.M006626200 originally published online September 7, 2000

Find articles, minireviews, Reflections and Classics on similar topics on the JBC Affinity Sites. Alerts: • When this article is cited • When a correction for this article is posted Click here to choose from all of JBC's e-mail alerts This article cites 50 references, 30 of which can be accessed free at http://www.jbc.org/content/275/50/39458.full.html#ref-list-1


Access the most updated version of this article at doi: 10.1074/jbc.M006626200